Tsubota Laboratory Incorporated Logo

Tsubota Laboratory Incorporated

R&D company developing treatments for ophthalmology and CNS disorders.

4890 | T

Overview

Corporate Details

ISIN(s):
JP3535700003
LEI:
Country:
Japan
Address:
新宿区信濃町35 慶應義塾大学信濃町キャンパス2号館9階CRIK信濃町E7

Description

Tsubota Laboratory Incorporated is a research and development company that originated as a startup from Keio University. It is engaged in the creation of pharmaceuticals and medical devices. The company's primary focus is on ophthalmology, developing solutions for conditions such as myopia, dry eye, and presbyopia. Additionally, it explores treatments for central nervous system (CNS) disorders and brain diseases. The corporate strategy centers on out-licensing its developed pipelines to commercial partners. A notable pipeline is a therapeutic candidate designed to curtail the progression of myopia.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 07:34
確認書
Japanese 9.0 KB
2025-11-12 07:33
半期報告書-第14期(2025/04/01-2026/03/31)
Japanese 195.3 KB
2025-06-27 04:35
臨時報告書
Japanese 23.3 KB
2025-06-26 09:02
確認書
Japanese 9.4 KB
2025-06-26 09:01
内部統制報告書-第13期(2024/04/01-2025/03/31)
Japanese 23.5 KB
2025-06-26 09:01
有価証券報告書-第13期(2024/04/01-2025/03/31)
Japanese 1.6 MB
2024-11-14 08:02
確認書
Japanese 9.0 KB
2024-11-14 08:02
半期報告書-第13期(2024/04/01-2025/03/31)
Japanese 201.7 KB
2024-06-27 04:10
内部統制報告書-第12期(2023/04/01-2024/03/31)
Japanese 22.8 KB
2024-06-27 04:09
確認書
Japanese 8.9 KB
2024-06-27 04:08
有価証券報告書-第12期(2023/04/01-2024/03/31)
Japanese 1.7 MB
2024-02-14 07:11
確認書
Japanese 9.0 KB
2024-02-14 07:10
四半期報告書-第12期第3四半期(2023/10/01-2023/12/31)
Japanese 160.1 KB
2023-11-13 07:06
確認書
Japanese 9.0 KB
2023-11-13 07:02
四半期報告書-第12期第2四半期(2023/07/01-2023/09/30)
Japanese 193.0 KB

Automate Your Workflow. Get a real-time feed of all Tsubota Laboratory Incorporated filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Tsubota Laboratory Incorporated

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Tsubota Laboratory Incorporated via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NanoGroup S.A. Logo
Develops nanotechnology-based medical solutions for oncology and transplantology.
Poland
NNG
NANO MRNA Co.,Ltd. Logo
Biotechnology firm creating and out-licensing IP for mRNA-based therapeutics.
Japan
4571
NANOVIRICIDES, INC. Logo
Clinical-stage biopharma developing broad-spectrum, nanomedicine-based antivirals.
United States of America
NNVC
Nautilus Biotechnology, Inc. Logo
Develops a proteome analysis platform to quantify proteins at the single-molecule level.
United States of America
NAUT
NeoImmuneTech, Inc. Logo
A clinical-stage biopharma developing T cell-focused immuno-therapeutics for diseases.
United States of America
950220
Neovacs Logo
Biotech firm developing immunotherapies and investing in BioTech and MedTech.
France
ALNEV
NewAmsterdam Pharma Co N.V. Logo
A clinical-stage biopharma developing therapies for metabolic diseases with unmet needs.
United States of America
NAMS
NextGen Biomed Ltd. Logo
Develops novel therapeutic delivery systems and pain-free auto-injectors.
Israel
NXGN
NEXTURNBIOSCIENCE Co., LTD Logo
Manufacturer of CNC automatic lathes and ultra-precision components for various industries.
South Korea
089140
NFL Biosciences Logo
Biopharmaceutical company developing botanical drug candidates for addiction treatment.
France
ALNFL

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.